Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica
New England Journal of Medicine · 2026
DOI: 10.1056/nejmoa2602567 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, 2026. Verfasst von John H Stone und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Inflammation, and Immunology, Massachusetts General Hospital, Boston. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Glucocorticoids, Interleukin-17, Polymyalgia Rheumatica. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Novartis Pharma AG, Basel, Switzerland.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Inflammation, and Immunology, Massachusetts General Hospital, Boston.
- Division of Rheumatology, Inflammation, and Immunology, Harvard Medical School, Boston.
- Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Berlin.
- Deutsches Rheuma-Forschungszentrum, Berlin.
- Centre Hospitalier Universitaire Brest, Université de Bretagne Occidentale, INSERM Unité Mixte de Recherche 1227, Brest, France.
- Department of Rheumatology, Waldfriede Hospital, Berlin.
ORCID-Profile: Frank Buttgereit, Robert Spiera
Förderung
- Novartis Pharma AG, Basel, Switzerland
Zitieren
APA
Stone, J. H., Buttgereit, F., Saraux, A., Schmidt, W. A., Dejaco, C., Spiera, R., Dasgupta, B., Drescher, E., Jordan, A., Novosad, L., Nakagomi, D., Koyama, Y., Duran-Barragan, S., Tracey, G., Ruyssen-Witrand, A., Rubbert Roth, A., Fang, J., Ng, J., Hiremath, R., …, & REPLENISH Investigators (2026). Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2602567
Vancouver
Stone JH, Buttgereit F, Saraux A, Schmidt WA, Dejaco C, Spiera R, et al. Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica. New England Journal of Medicine. 2026. doi:10.1056/nejmoa2602567
BibTeX
@article{Stone2026,
author = {Stone, John H and Buttgereit, Frank and Saraux, Alain and Schmidt, Wolfgang A and Dejaco, Christian and Spiera, Robert and Dasgupta, Bhaskar and Drescher, Edit and Jordan, Andrew and Novosad, Libor and Nakagomi, Daiki and Koyama, Yoshinobu and Duran-Barragan, Sergio and Tracey, Gerald and Ruyssen-Witrand, Adeline and Rubbert Roth, Andrea and Fang, Juanzhi and Ng, Jennifer and Hiremath, Renuka and Raffner, Roselyne and Martin, Ruvie and Napoletano, Silvia and Huang, Songqiao and Storim, Julian and Patekar, Manmath and REPLENISH Investigators, REPLENISH Investigators},
title = {Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica},
journal = {New England Journal of Medicine},
year = {2026},
doi = {10.1056/nejmoa2602567}
}
EUVIMED